transmedТрансляционная медицинаTranslational Medicine2311-44952410-5155Almazov National Medical Research Centre, Saint Petersburg, Russia10.18705/2311-4495-2014-0-4-5-10transmed-44Research ArticleЭНДОКРИНОЛОГИЯENDOCRINOLOGYНовые технологии в профилактике и лечении сахарного диабета 1 типаNEW TECHNOLOGIES IN PREVENTION AND TREATMENT OF DIABETES TYPE 1ГринёваЕлена НиколаевнаGrinevaE. N.grineva_e@mail.ruКравчукЕкатерина НикодимовнаKravchukE. N.noemail@neicon.ruФГБУ «Федеральный медицинский исследовательский центр им. В.А. Алмазова» Минздрава РоссииРоссияFederal Almazov Medical Research CentreRussian Federation20142312201604510Copyright © Гринёва Е.Н., Кравчук Е.Н., 20162016Гринёва Е.Н., Кравчук Е.Н.Grineva E.N., Kravchuk E.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://transmed.almazovcentre.ru/jour/article/view/44

Сахарный диабет 1А типа (СД1) является аутоиммунным заболеванием, характеризующимся деструкцией бета-клеток с развитием абсолютной инсулиновой недостаточности. Единственным эффективным способом терапии СД1 в настоящий момент является пожизненная заместительная инсулинотерапия. К сожалению, успешных методов профилактики и лечения СД1 в настоящий момент не существует. В данном обзоре будут рассмотрены результаты наиболее современных исследований по первичной, вторичной и третичной профилактике СД1.

Diabetes mellitus type 1 (DM1) is an autoimmune disease with beta-cell destruction and absolute insulin deficiency. The most effective therapy of DM1 is lifelong vicarous insulinterapy. Unfortunately, there is no successful methods of prophylaxis and treatment of DM1. In this review we will discuss results of modern trials of primary, secondary and tertiary prophylaxis of DM1.

сахарный диабетпрофилактикабета-клеткаинсулинdiabetes mellituspreventionbeta-cellinsulinReferencesYoon J.W., Jun H.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus / Ann. N.Y. Acad Sci. - 2001. - Vol. 928. - P. 200-211.Yoon J.W., Jun H.S. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus / Ann. N.Y. Acad Sci. - 2001. - Vol. 928. - P. 200-211.Achenbach P., Bonifacio E., Koczwara K. et al. Natural history of type 1 diabetes / Diabetes. - 2005. - Vol. 54. - P. 25-31.Achenbach P., Bonifacio E., Koczwara K. et al. Natural history of type 1 diabetes / Diabetes. - 2005. - Vol. 54. - P. 25-31.Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes / Nature. - 2010. - Vol. 29, № 464. - P. 1293-1300.Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes / Nature. - 2010. - Vol. 29, № 464. - P. 1293-1300.Skyler J.S. Primary and secondary prevention of Type 1 diabetes / Diabet. Med. - 2013. - Vol. 30, № 2. - P. 161-169.Skyler J.S. Primary and secondary prevention of Type 1 diabetes / Diabet. Med. - 2013. - Vol. 30, № 2. - P. 161-169.Gerstein H.C. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature / Diabetes Care. - 1994. - Vol. 17. - P. 13-19.Gerstein H.C. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature / Diabetes Care. - 1994. - Vol. 17. - P. 13-19.Virtanen S.M., Bärlund S., Salonen M. et al. Feasibility and compliance in a nutritional primary prevention trial in infants at increased risk for type 1 diabetes / Acta Paediatr. - 2011. - Vol. 100, № 4. - P. 557-564.Virtanen S.M., Bärlund S., Salonen M. et al. Feasibility and compliance in a nutritional primary prevention trial in infants at increased risk for type 1 diabetes / Acta Paediatr. - 2011. - Vol. 100, № 4. - P. 557-564.TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) / Pediatr. Diabetes. - 2007. - Vol. 8. - P. 117-137.TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) / Pediatr. Diabetes. - 2007. - Vol. 8. - P. 117-137.Vaarala O., Ilonen J., Ruohtula T. et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study / Arch. Pediatr. Adolesc. Med. - 2012. - Vol. 166. - P. 608-614.Vaarala O., Ilonen J., Ruohtula T. et al. Removal of bovine insulin from cow’s milk formula and early initiation of beta-cell autoimmunity in the FINDIA pilot study / Arch. Pediatr. Adolesc. Med. - 2012. - Vol. 166. - P. 608-614.Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis / Arch. Dis. Child. - 2008. - Vol. 93. - P. 512-517.Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis / Arch. Dis. Child. - 2008. - Vol. 93. - P. 512-517.Schmid S., Buuck D., Knopff A. et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten / Diabetologia. - 2004. - Vol. 47. - Р. 1130-1131.Schmid S., Buuck D., Knopff A. et al. BABYDIET, a feasibility study to prevent the appearance of islet autoantibodies in relatives of patients with type 1 diabetes by delaying exposure to gluten / Diabetologia. - 2004. - Vol. 47. - Р. 1130-1131.Chase H.P., Lescheck E., Rafkin-Mervis L. et al. Nutritional intervention to prevent (NIP) type 1 diabetes: a pilot trial / Infant. Child. Adolesc. Nutr. - 2009. - Vol. 1. - P. 98-107.Chase H.P., Lescheck E., Rafkin-Mervis L. et al. Nutritional intervention to prevent (NIP) type 1 diabetes: a pilot trial / Infant. Child. Adolesc. Nutr. - 2009. - Vol. 1. - P. 98-107.Achenbach P., Barker J., Bonifacio E., Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization / Curr. Diab. Rep. - 2008. - Vol. 8, № 2. - P. 87-93.Achenbach P., Barker J., Bonifacio E., Pre-POINT Study Group. Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization / Curr. Diab. Rep. - 2008. - Vol. 8, № 2. - P. 87-93.Lazarow A. Protection against alloxan diabetes / Anat. Rec. - 1947. - Vol. 97. - P. 353.Lazarow A. Protection against alloxan diabetes / Anat. Rec. - 1947. - Vol. 97. - P. 353.Dulin W.E., Wyse B.M. Studies of ability of compounds to block the diabetogenic activity of streptozotocin / Diabetes. - 1969. - Vol. 18. - P. 459-466.Dulin W.E., Wyse B.M. Studies of ability of compounds to block the diabetogenic activity of streptozotocin / Diabetes. - 1969. - Vol. 18. - P. 459-466.Yamada K., Nonaka K., Hanafusa T. et al. Preventive and therapeutic aspects of large dose nicotinamide injections on diabetes associated with insulitis: an observation in non-obese diabetic (NOD) mice / Diabetes. - 1982. - Vol. 31. - P. 749-753.Yamada K., Nonaka K., Hanafusa T. et al. Preventive and therapeutic aspects of large dose nicotinamide injections on diabetes associated with insulitis: an observation in non-obese diabetic (NOD) mice / Diabetes. - 1982. - Vol. 31. - P. 749-753.Elliott R.B., Pilcher C.C., Stewart A. et al. The use of nicotinamide treatment in the prevention of type 1 diabetes / Ann. NY Acad. Sci. - 1993. - Vol. 696. - P. 333-341.Elliott R.B., Pilcher C.C., Stewart A. et al. The use of nicotinamide treatment in the prevention of type 1 diabetes / Ann. NY Acad. Sci. - 1993. - Vol. 696. - P. 333-341.Lampeter E.F., Klinghammer A., Scherbaum W.A. et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group / Diabetes. - 1998. - Vol. 47. - P. 980-984.Lampeter E.F., Klinghammer A., Scherbaum W.A. et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group / Diabetes. - 1998. - Vol. 47. - P. 980-984.European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes / Lancet. - 2004. - Vol. 363. - P. 925-931.European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomized controlled trial of intervention before the onset of type 1 diabetes / Lancet. - 2004. - Vol. 363. - P. 925-931.Diabetes Prevention Trial - Type 1 Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus / N. Engl. J. Med. - 2002. - Vol. 346. - P. 1685-1691.Diabetes Prevention Trial - Type 1 Study Group. Effects of insulin in relatives of patients with Type 1 diabetes mellitus / N. Engl. J. Med. - 2002. - Vol. 346. - P. 1685-1691.Thrower S.L., James L., Hall W. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-inman Phase I safety study / Clin. Exp. Immunol. - 2009. - Vol. 155. - P. 156-165.Thrower S.L., James L., Hall W. et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-inman Phase I safety study / Clin. Exp. Immunol. - 2009. - Vol. 155. - P. 156-165.NCT01122446. Diabetes Prevention - Immune Tolerance (DIAPREV-IT) / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (December 2012).NCT01122446. Diabetes Prevention - Immune Tolerance (DIAPREV-IT) / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (December 2012).Carel J.C., Boitard C., Eisenbarth G. et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children / J. Autoimmun. - 1996. - Vol. 9. - P. 739-745.Carel J.C., Boitard C., Eisenbarth G. et al. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children / J. Autoimmun. - 1996. - Vol. 9. - P. 739-745.NCT 01030861. Teplizumab for prevention of Type diabetes in relatives ‘at-risk’ / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (дата обращения: 12.12.2012).NCT 01030861. Teplizumab for prevention of Type diabetes in relatives ‘at-risk’ / [Электронный ресурс]. URL: http://www.ClinicalTrials.gov (дата обращения: 12.12.2012).Assan R., Feutren G., Debray-Sachs M. et al. Metabolic and immunological effects of cyclosporine in recently diagnosed type 1 diabetes mellitus / Lancet. - 1985. - Vol. 1. - P. 67-71.Assan R., Feutren G., Debray-Sachs M. et al. Metabolic and immunological effects of cyclosporine in recently diagnosed type 1 diabetes mellitus / Lancet. - 1985. - Vol. 1. - P. 67-71.Stiller C., Dupré J., Gent M. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset / Science. - 1984. - Vol. 223. - P. 1362-1367.Stiller C., Dupré J., Gent M. et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset / Science. - 1984. - Vol. 223. - P. 1362-1367.Bougneres P.F. , Landais P., Boisson C. et al. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low-dose cyclosporin / Diabetes. - 1990. - Vol. 39. - P. 1264-1272.Bougneres P.F. , Landais P., Boisson C. et al. Limited duration of remission of insulin dependency in children with recent overt type 1 diabetes treated with low-dose cyclosporin / Diabetes. - 1990. - Vol. 39. - P. 1264-1272.Skyler J.S., Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man / Diabetes. - 2011. - Vol. 60, № 1. - P. 1-8.Skyler J.S., Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man / Diabetes. - 2011. - Vol. 60, № 1. - P. 1-8.Sherry N., Hagopian W., Ludvigsson J. et al. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized placebocontrolled trial / Lancet. - 2011. - Vol. 378. - P. 487-497.Sherry N., Hagopian W., Ludvigsson J. et al. Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized placebocontrolled trial / Lancet. - 2011. - Vol. 378. - P. 487-497.Orban T., Bundy B., Becker D.J. Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment / Diabetes Care. - 2014. - Vol. 37, № 4. - P. 1069-1075.Orban T., Bundy B., Becker D.J. Type 1 Diabetes TrialNet Abatacept Study Group. Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1 Diabetes: Follow-up 1 Year After Cessation of Treatment / Diabetes Care. - 2014. - Vol. 37, № 4. - P. 1069-1075.Voltareli J.C., Couri C.E.B., Stracieri A.B.P.L. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2007. - Vol. 297. - P. 1568-1576.Voltareli J.C., Couri C.E.B., Stracieri A.B.P.L. et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2007. - Vol. 297. - P. 1568-1576.Couri C.E.B., Oliveira M.C.B., Stracieri A.B.P.L. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2009. - Vol. 301. - P. 1573-1579.Couri C.E.B., Oliveira M.C.B., Stracieri A.B.P.L. et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus / JAMA. - 2009. - Vol. 301. - P. 1573-1579.Leal A.M.O., Oliveira M.C., Couri C.E.B. et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT / Bone Marrow Transplant. - 2012. - Vol. 47. - P. 467-468.Leal A.M.O., Oliveira M.C., Couri C.E.B. et al. Testicular function in patients with type 1 diabetes treated with high-dose CY and autologous hematopoietic SCT / Bone Marrow Transplant. - 2012. - Vol. 47. - P. 467-468.Ludvigsson J., Faresjö M., Hjorth M. et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes / N. Engl. J. Med. - 2008. - Vol. 359, № 18. - P. 1909-1920.Ludvigsson J., Faresjö M., Hjorth M. et al. GAD treatment and insulin secretion in recent-onset Type 1 diabetes / N. Engl. J. Med. - 2008. - Vol. 359, № 18. - P. 1909-1920.Wherrett D.K., Bundy B., Becker D.J. et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial / Lancet. - 2011. - Vol. 378, № 9788. - P. 319-327.Wherrett D.K., Bundy B., Becker D.J. et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset Type 1 diabetes: a randomised double-blind trial / Lancet. - 2011. - Vol. 378, № 9788. - P. 319-327.Ludvigsson J., Krisky D., Casas R. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus / N. Engl. J. Med. - 2012. - Vol. 366. - P. 433-442.Ludvigsson J., Krisky D., Casas R. et al. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus / N. Engl. J. Med. - 2012. - Vol. 366. - P. 433-442.Raz I., Elias D., Avron A. et al. Beta-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial / Lancet. - 2001. - Vol. 358. - P. 1749-1753.Raz I., Elias D., Avron A. et al. Beta-cell function in new-onset Type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial / Lancet. - 2001. - Vol. 358. - P. 1749-1753.Schloot N.C., Meierhoff G., Lengyel C. et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomized, double-blind Phase II trials / Diabetes Metab. Res. Rev. - 2007. - Vol. 23, № 4. - P. 276-285.Schloot N.C., Meierhoff G., Lengyel C. et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus Type 1: two prospective, randomized, double-blind Phase II trials / Diabetes Metab. Res. Rev. - 2007. - Vol. 23, № 4. - P. 276-285.Raz I., Ziegler A.G., Linn T. Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial / Diabetes Care. - 2014. - Vol. 37, № 5. - P. 1392-1400.Raz I., Ziegler A.G., Linn T. Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial / Diabetes Care. - 2014. - Vol. 37, № 5. - P. 1392-1400.

The authors declare that there are no conflicts of interest present.